

November 1, 1967

Dr. Carl Salzman
ECDEU, Psychopharmacology Research Branch
National Institutes of Mental Health
Bethesda, Maryland

Dear Dr. Salzman:

Thank you for your letter of October 24. The list of studies currently in progress has been markedly augmented during the past few months. Enclosed are copies of research plan reports for each of the studies currently in progress and those that will be undertaken during the next two months.

Of the two cyclazocine studies, the first in narcotic addiction has been completed and two reports have been prepared. One has appeared in the *Journal of the American Medical Association* during the past month and the second is in press in the *American Journal of Psychiatry*. The first study of cyclazocine in depressive disorders is now being completed and the second has already been planned.

The fluphenazine decanoate study is in progress, with the protocol having been modified so that after 20 cases fluphenazine enanthate will be introduced as a comparative drug.

We have recently begun to use the biometric laboratory form. I would be pleased to have you and Bill Guy visit with us at your discretion.

I look forward to seeing you in San Juan.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp